SCHEMBL3014880

SCHEMBL3014880

O=S(=O)(c1cccc(C(F)(F)F)c1)N1CCN(c2nc(-c3ccc(Cl)c(Cl)c3)cs2)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
AR P10275 2/20 0.54
HTT P42858 1/20 0.53
MAPT P10636 3/20 0.52
USP2 O75604 1/20 0.52
RECQL P46063 1/20 0.52
HSD17B10 Q99714 1/20 0.52
GBA1 P04062 2/20 0.49
POLB P06746 1/20 0.49
HSD11B1 P28845 3/20 0.49
KDM4E B2RXH2 1/20 0.49
MEN1 O00255 2/20 0.48
LMNA P02545 2/20 0.48
KMT2A Q03164 2/20 0.48
KDM1A O60341 1/20 0.48
MAPK1 P28482 2/20 0.46
PKM P14618 1/20 0.45
PKLR P30613 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3655559 0.94 POLB (0.51) ALDH1A1SMN1; SMN2L3MBTL1ARHTT
SCHEMBL3011390 0.93 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2L3MBTL1ARHTT
SCHEMBL3015353 0.93 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2L3MBTL1ARHTT
SCHEMBL3002525 0.91 SMN1; SMN2 (0.59) ALDH1A1SMN1; SMN2L3MBTL1ARHTT
SCHEMBL3010287 0.90 HTT (0.53) ALDH1A1SMN1; SMN2L3MBTL1ARHTT
SCHEMBL3008043 0.89 ALDH1A1 (0.58) ALDH1A1SMN1; SMN2L3MBTL1ARHTT
SCHEMBL3018379 0.88 HTT (0.62) ALDH1A1SMN1; SMN2L3MBTL1ARHTT
SCHEMBL3010748 0.88 POLB (0.55) ALDH1A1SMN1; SMN2L3MBTL1ARHTT
SCHEMBL3010804 0.88 ALDH1A1 (0.59) ALDH1A1SMN1; SMN2L3MBTL1ARHTT
SCHEMBL3007171 0.87 ALDH1A1 (0.64) ALDH1A1SMN1; SMN2L3MBTL1ARHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA ALDH1A1 3510/4885SMN1; SMN2 1/4885L3MBTL1 1847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.